Interventional, Open-label, Fixed-dose Multiple Administration Study to Evaluate Long-term Treatment With Eptinezumab in Patients With Chronic Cluster Headache
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Eptinezumab (Primary)
- Indications Cluster headache
- Focus Adverse reactions; Registrational
- Acronyms CHRONICLE
- Sponsors Lundbeck A/S
- 13 Jun 2024 According to Lundbeck media release, company announced data presentations of this trial at the 66th Annual Scientific Meeting of the American Headache Society (AHS) taking place in San Diego, Calif., June 13-16, 2024.
- 12 Jul 2023 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.